Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Leukemia 13Myelodysplastic Syndromes 12Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Non-Hodgkin 5Hematologic Neoplasms 5Leukemia, Promyelocytic, Acute 4Leukemia, Myelomonocytic, Chronic 4Congenital Abnormalities 4Recurrence 3Neoplasms 3Leukemia, Myelomonocytic, Juvenile 3Leukemia, Myelomonocytic, Acute 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Leukemia, Biphenotypic, Acute 3Hodgkin Disease 3Primary Myelofibrosis 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Solid Tumors 1Philadelphia Chromosome 1Pathologic Complete Response 1Neutropenia 1

Interventions

Cyclophosphamide 38fludarabine 30Rituximab 26obinutuzumab 10Bendamustine Hydrochloride 10fludarabine phosphate 9pembrolizumab 8Specimen Handling 7Etoposide 7venetoclax 6Vincristine 6Prednisone 6Magnetic Resonance Spectroscopy 6Leukapheresis 6Lenalidomide 6ibrutinib 5Inotuzumab Ozogamicin 5Immunotherapy, Adoptive 5Doxorubicin 5Biopsy 5ublituximab 4tazemetostat 4glofitamab 4Interleukin-2 4Dexamethasone 4Cytarabine 4pomalidomide 3polatuzumab vedotin 3Radiation 3Nivolumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, B-Cell × Clofarabine × Clear all
NCT00338494 2015-01-29

Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma

Yale University

Phase 1 Completed
16 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡